Literature DB >> 4031383

Differential effects of acute DA receptor blockade with domperidone on LH and TSH release in patients with hyperprolactinemia.

J R Peters, M D Rodriguez-Arnao, S M Foord, C Edwards, C Dieguez, S Woodhead, R Hall, M F Scanlon.   

Abstract

Since dopamine (DA) has been implicated in the inhibitory control of both TSH and LH, we have compared TSH and LH levels following dopamine (DA) receptor blockade with domperidone in patients with hyperprolactinemia due to presumed prolactinomas. Eight euthyroid patients (aged 19-37 yr) with presumed prolactinomas each received domperidone (10 mg iv) at 11:00 and 23:00 h and tests were separated by at least one week. Basal TSH levels were significantly greater at 23:00 than at 11:00 h (2.7 +/- 0.5 vs 1.7 +/- 0.4 mU/l, mean +/- SE, p less than 0.01) whereas basal LH levels did not differ. All subjects showed clear rises in basal TSH levels following drug administration and these were significantly greater at 23:00 than at 11:00 h (p less than 0.02 at each time point). In contrast there was no alteration in LH levels following drug administration at either time of day. These data suggest that the mechanisms underlying the dopaminergic control of TSH and LH are different in these patients. Furthermore the data argue against an anterior pituitary or median eminence site of action of DA in the inhibition of LH release in hyperprolactinemia since domperidone does not penetrate the blood brain barrier to any appreciable extent.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4031383     DOI: 10.1007/BF03350675

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  15 in total

1.  Studies on the mechanism of the dopamine-mediated inhibition of prolactin secretion.

Authors:  R M MacLeod; J E Lehmeyer
Journal:  Endocrinology       Date:  1974-04       Impact factor: 4.736

2.  Circadian variation of the serum thyrotropin level in normal subjects.

Authors:  J Weeke
Journal:  Scand J Clin Lab Invest       Date:  1973-05       Impact factor: 1.713

3.  Dopaminergic modulation of circadian thyrotropin rhythms and thyroid hormone levels in euthyroid subjects.

Authors:  M F Scanlon; A P Weetman; M Lewis; M Pourmand; M D Rodriguez-Arnao; D R Weightman; R Hall
Journal:  J Clin Endocrinol Metab       Date:  1980-12       Impact factor: 5.958

4.  Domperidone, a novel and safe gastrokinetic anti-nauseant for the treatment of dyspepsia and vomiting.

Authors:  A J Reyntjens; C J Niemegeers; J M Van Nueten; P Laduron; J Heykants; K H Schellekens; R Marsboom; A Jageneau; A Broekaert; P A Janssen
Journal:  Arzneimittelforschung       Date:  1978

5.  Altered dopaminergic regulation of thyrotrophin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function.

Authors:  M F Scanlon; M D Rodriguez-Arnao; A M McGregor; D Weightman; M Lewis; D B Cook; A Gomez-Pan; R Hall
Journal:  Clin Endocrinol (Oxf)       Date:  1981-02       Impact factor: 3.478

6.  Effects of a dopamine antagonist on the release of gonadotropin and prolactin in normal women and women with hyperprolactinemic anovulation.

Authors:  M E Quigley; S J Judd; G B Gilliland; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1979-04       Impact factor: 5.958

7.  Tests of prolactin secretion in diagnosis of prolactinomas.

Authors:  E A Cowden; J G Ratcliffe; J A Thomson; P Macpherson; D Doyle; G M Teasdale
Journal:  Lancet       Date:  1979-06-02       Impact factor: 79.321

8.  Dopamine receptors on intact anterior pituitary cells in culture: functional association with the inhibition of prolactin and thyrotropin.

Authors:  S M Foord; J R Peters; C Dieguez; M F Scanlon; R Hall
Journal:  Endocrinology       Date:  1983-05       Impact factor: 4.736

9.  The relationship between circadian variations in circulating thyrotrophin, thyroid hormones and prolactin.

Authors:  V Chan; A Jones; P Liendo-Ch; A McNeilly; J Landon; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  1978-10       Impact factor: 3.478

10.  Evidence for increased dopaminergic inhibition of secretion of thyroid-stimulating hormone in hyperprolactinemic patients with pituitary microadenoma.

Authors:  M E Quigley; S S Yen
Journal:  Am J Obstet Gynecol       Date:  1980-07-15       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.